Home » Stocks » BMRN

BioMarin Pharmaceutical Inc. (BMRN)

Stock Price: $78.15 USD 0.19 (0.24%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $77.95 -0.20 (-0.26%) Nov 25, 7:59 PM

Stock Price Chart

Key Info

Market Cap 14.19B
Revenue (ttm) 1.86B
Net Income (ttm) 852.03M
Shares Out 181.53M
EPS (ttm) 4.56
PE Ratio 17.14
Forward PE 52.63
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $78.15
Previous Close $77.96
Change ($) 0.19
Change (%) 0.24%
Day's Open 78.48
Day's Range 77.54 - 79.38
Day's Volume 865,544
52-Week Range 68.25 - 131.95

More Stats

Market Cap 14.19B
Enterprise Value 14.13B
Earnings Date (est) Feb 25, 2021
Ex-Dividend Date n/a
Shares Outstanding 181.53M
Float 179.89M
EPS (basic) 4.71
EPS (diluted) 4.56
FCF / Share 0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield 5.83%
FCF Yield 0.63%
Payout Ratio n/a
Shares Short 11.68M
Short Ratio 8.56
Short % of Float 6.49%
Beta 0.67
PE Ratio 17.14
Forward PE 52.63
P/FCF Ratio 159.08
PS Ratio 7.62
PB Ratio 3.47
Revenue 1.86B
Operating Income -1.09M
Net Income 852.03M
Free Cash Flow 89.18M
Net Cash 57.22M
Net Cash / Share 0.32
Gross Margin 33.80%
Operating Margin -0.06%
Profit Margin 45.70%
FCF Margin 4.79%
ROA -0.80%
ROE 23.91%
ROIC 0.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (25)

Buy 13
Overweight 2
Hold 10
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$108.73*
(39.13% upside)
Low
80.0
Current: $78.15
High
187.0
Target: 108.73
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,7041,4911,3141,117890749548501441376
Revenue Growth14.27%13.52%17.62%25.5%18.77%36.61%9.54%13.45%17.3%-
Gross Profit1,3451,1761,072907738627460409357306
Operating Income-100-124-14.70-803-111-92.89-156-110-33.890.54
Net Income-23.85-77.21-117-630-172-134-176-114-53.84206
Shares Outstanding179177174166160146138120112103
Earnings Per Share-0.13-0.44-0.67-3.81-1.07-0.92-1.28-0.95-0.481.73
Operating Cash Flow48.2620.21-8.76-228-219-70.42-57.3417.6118.4218.75
Capital Expenditures-145-145-199-148-228-117-65.19-44.57-154-49.46
Free Cash Flow-96.76-124-208-376-447-187-123-26.96-136-30.72
Cash & Equivalents7541,0841,396790593945785448195274
Total Debt8488301,174683662643656348348378
Net Cash / Debt-94.31254221106-69.6730212999.58-153-103
Assets4,6904,4274,6334,0243,7292,4752,2441,5681,3061,263
Liabilities1,5681,4591,8241,2571,329947903553533545
Book Value3,1222,9682,8092,7662,4011,5281,3411,016773717
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BioMarin Pharmaceutical Inc.
Country United States
Employees 3,001
CEO Jean-Jacques Bienaimé

Stock Information

Ticker Symbol BMRN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BMRN
IPO Date July 23, 1999

Description

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Company; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.